Progress through collaboration

ANCA-associated vasculitis (AAV) includes three disease subtypes with partly overlapping clinical manifestations: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). This Review article provides an update on the diagnosis and classification of AAV, discussing parameters for assessing disease activity and predicting outcomes towards a personalized medicine approach.

This Perspective article discusses the stratification of patients with knee osteoarthritis (OA) in the context of current guidelines, biomarkers and emerging and future developments of targeted treatment. The authors aim to highlight how these novel developments can enhance the stratification of patients with knee OA to improve patient outcomes.

This Review summarizes clinical effectiveness, health economics and safety data on the parathyroid hormone receptor agonists teriparatide and abaloparatide, discussing potential strategies and drug combinations to achieve best outcomes in patients with osteoporosis.

In this Perspective, the authors and the members of the Integrated Multidisciplinary Paediatric Autoimmunity and Cell Therapy (IMPACT) working group discuss specific considerations for the use of chimeric antigen receptor (CAR) T cell therapies in paediatric patients with rheumatic diseases.

The diagnosis, treatment and management of systemic sclerosis (SSc) remains challenging, owing to the complexity of this disease. In this Perspective, an international group of experts discuss the future of SSc research and how the advent of innovative technologies will advance research into and understanding of SSc.

This Review discusses obstacles to health care equity in rheumatic disease, including access to health care and the use of inaccurate language when labelling population groups. The authors also highlight the siloing of biological and epidemiological research in rheumatology. They conclude with recommendations for achieving equitable precision medicine.

Large partnerships between academia and industry are emerging as a possible solution to the problems surrounding stratified medicine. In this Perspectives article, the members of the RA-MAP Consortium reflect on the challenges and benefits of working in such a partnership.

Biobanks are important tools for researchers investigating paediatric rheumatic diseases. In this Opinion article, the authors outline how standardization can improve sample and data sharing, providing examples from international biorepository networks.

Progress has been astonishing, but the need for personalized care can only be addressed through a universal focus on diversity and equity in rheumatology research.

Both rheumatology and the publishing environment have seen tremendous changes over the past two decades. Here, the first Editor in-Chief reflects on the challenges faced by this journal and what it has taken to remain at the forefront of the field.

In the past two decades the field of hand osteoarthritis (OA) has moved from resignation to action. Despite progress, such as the recognition of the phenotypic heterogeneity of hand OA (including inflammation- and/or metabolic syndrome-associated hand OA) and the standardization of imaging and treatment outcomes, challenges remain in achieving truly disease-modifying therapies.

The collective priorities of the rheumatology field represent the lived experience, and therefore diversity of its members. The ‘mould’ of rheumatology, that is, its culture, structures and expectations, was not created for or by women, but women have slowly changed this mould to make space for diverse perspectives.

The future of rheumatology research will be defined by the growing era of personalized and stratified medicine, with a focus on establishing drug-free remission. In the face of substantial global upheaval, now is the time to ensure no patient group is left behind by prioritizing research equity and inclusion.

Despite having a robust drug development pipeline, lupus remains far behind other rheumatic and autoimmune conditions for which dozens of targeted therapies have been developed. Addressing the pervasive, long-standing challenges impeding the field requires a paradigm shift and a patient-powered, community-wide approach, exemplified by the Lupus Accelerating Breakthroughs Consortium (Lupus ABC).

In this Consensus Statement, an international group of experts and patient representatives validates and endorses the transition from the term ‘Sjögren syndrome’ to ‘Sjögren disease’, and issue several additional recommendations regarding the nomenclature of this disorder.

In this Evidence-Based Guideline article, an international multidisciplinary working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases presents recommendations for the diagnosis, monitoring and treatment of osteoporosis in men.

In this Evidence-Based Guideline article, an international, multidisciplinary group of experts presents evidence-based consensus recommendations on screening for cancer in patients with adult-onset idiopathic inflammatory myopathy, addressing cancer risk stratification, screening modalities and screening frequency.

This Evidence-Based Guideline presents the first Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis, addressing therapeutic targets, the use of pharmacological and non-pharmacological interventions and monitoring of patients.

In this Consensus Statement, the Treatment Response Measure for Systemic Lupus Erythematosus Consortium presents the initial outcomes of a project to develop a clinical outcome assessment that can contribute to the regulatory approval process for therapeutic agents via its incorporation in end points of clinical trials in systemic lupus erythematosus.

This article presents the first Evidence-Based Guideline dedicated specifically to the diagnosis and management of eosinophilic granulomatosis with polyangiitis. The 16 statements and five overarching principles cover the diagnosis and staging, treatment, outcome and follow-up of eosinophilic granulomatosis with polyangiitis.

This Evidence-Based Guideline presents the latest treatment recommendations for medication selection in psoriatic arthritis (PsA), covering the six clinical domains of PsA, related conditions and associated comorbidities, and reflecting important advances in the field since the previous update.